New company to advance cerebral palsy therapy
A new regenerative medicine company is set to develop a novel cell and gene therapy targeting paediatric cerebral palsy (CP).
Kidswell USA has been formed by a partnership between biosimilars and cell therapies company Kidswell Bio Corporation and corporate development advisor Treehill Partners.
In the new company, Kidswell and Treehill aim to advance their lead programme, SQ-SHED, through clinical development. The companies say SQ-SHED has already shown strong initial signals of clinical efficacy in CP.
An estimated one in 345 children has CP in the US, with the National Institutes of Health (NIH) reporting that approximately 8,000 to 12,000 infants born each year develop the condition. Currently, only symptomatic treatments are available for CP patients, highlighting the need for new disease modifying therapeutics.
Kidswell and Treehill have selected Thermo Fisher Scientific as their preferred development service partner for SQ-SHED, with the development programme focussed specifically on the US market.
“Kidswell is seeking to develop its most innovative therapies for the US market, and to accelerate this process we have selected partners that will enable us to jointly create a clinical development roadmap,” said Shinya Kurebayashi, President & CEO, Kidswell Bio Corporation.
“This roadmap will provide the best opportunities for success with the most financially efficient routes, and provide therapies that are commercially viable for the market. This will result in new therapies for underserved indications where patients have few alternative therapeutic options.”
“Too many promising therapies fail unnecessarily in clinical development or never reach patients due to inefficient development pathways and poor capital discipline,” added Ali Pashazadeh, CEO and Founder of Treehill Partners.
“Partnering with Kidswell will speed up the advancement of its cell therapy for paediatric cerebral palsy, a programme with meaningful clinical potential and significant unmet need. This collaboration adds another high-quality asset to Treehill’s growing portfolio, where we apply strategic development expertise to efficiently progress therapies toward approval and value-creating commercialisation.”
